The
CLINUVEL Group
We are a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.
What is a Stroke?
Annual Report 2022
On 30 August 2022 CLINUVEL announced its latest Annual Report, highlighting record operating profits and progress in the growth and expansion strategy of the company.
Latest News
Confirming the potential of our products
to repair UV-induced DNA damage
Evaluating afamelanotide
as treatment for AIS
Pioneering the concept of
medicinal photoprotection
We aim to grow our knowhow continuously
and establish a learned community
doses of SCENESSE® administered
>1,400 individuals have received SCENESSE®
Pharmaceutical Technology
CLINUVEL is developing novel pharmaceuticals with known photoprotective, antioxidative, anti-inflammatory, vasoactive and anti-oncotic properties. Read more.
PHOTOMEDICINE
Light and the
Environment
CLINUVEL is a leader in the field of photomedicine, investigating the interaction of light and human biology and pioneering the concept of medicinal photoprotection – protecting skin from light. The concentration of resources and efforts on photomedicine has made CLINUVEL a leader in the field.
DNA Repair
DNA Repair Program:
Xeroderma Pigmentosum
XP patients exhibit extreme deficiency in repair of UV-provoked damage to the DNA helix within the nucleus of skin cells. If left unrepaired, damaged DNA replicates and significantly increases the risk of skin cancers, including melanoma, in these patients.
Media Coverage
Media coverage on third-party sites can be found at the links below (please note that subscriptions may be required):